The global hematocrit testing market size was estimated at USD 1.25 billion in 2024 and is projected to reach USD 2.01 billion by 2033, growing at a CAGR of 5.30% from 2025 to 2033, driven by a rising prevalence of hematological and chronic diseases, including anemia, blood loss monitoring (trauma/surgery), polycythemia screening, and chronic disease management (kidney disease, cancer). According to the 2025 PubMed Central study, anemia affects approximately 42% of patients with chronic kidney disease (CKD) in Asia.
It has also been estimated that as CKD progresses, anemia rates can go up to 80% in late-stage disease. In the same year, a systematic review reported that the prevalence is up to 65% of cancer patients globally, spanning multiple tumor types. Given these disease patterns, demand for hematocrit testing continues to rise. Because hematocrit is a core component of the CBC panel used to screen and monitor these conditions, the growing disease burden is increasing demand for hematocrit testing, thereby driving the rapid growth of the global hematocrit testing market.
The growing use of automated and digital hematology analyzers is propelling market growth as healthcare systems transition to high-throughput, precision-driven diagnostic platforms. In August 2024, Abbott received FDA clearance for its Alinity h-series hematology instruments, enabling advanced, fully automated CBC and hematocrit testing with faster turnaround times and enhanced workflow efficiency. The platform combines smart sample management, digital reporting, and high analytical sensitivity to reduce manual intervention while improving laboratory performance. This trend is consistent with the broader global shift toward digitized hematology, in which AI-assisted interpretation, automated quality control, and remote connectivity are becoming standard features in modern laboratories. These innovations significantly improve testing capacity, accuracy, and clinical reliability. Therefore, the market is constantly expanding due to the increased adoption of automated analyzers, the modernization of diagnostic laboratories, and the rising need for efficient, high-volume hematological testing.
The market is experiencing strong growth opportunities as it transitions to point-of-care (POC) hematocrit testing. Rapid, near-patient diagnostics are becoming increasingly important in emergency departments, ambulances, intensive care units, and rural clinics, where immediate hematocrit assessment facilitates faster decision-making for trauma care, anemia detection, dehydration assessment, and surgical blood-loss monitoring. Rising demand for faster turnaround times is driving the adoption of portable, user-friendly hematology analyzers. For instance, in August 2023, the FDA approved PixCell Medical's HemoScreen, a point-of-care CBC device that enables direct capillary sampling and provides rapid hematocrit results, significantly improving ease of use and testing throughput. These advancements reduce manual steps, shorten wait times, and increase access to diagnostic testing in decentralized settings. As healthcare systems prioritize faster triage, decentralized workflows, and operational efficiency, the use of point-of-care hematocrit testing increases. This ongoing shift is driving overall market growth by enhancing patient outcomes and enabling real-time clinical decision support.
According to a 2024 BMC Central study, the overall prevalence of anemia among elderly people ranges between 10% and 24%, indicating a significant baseline burden. The risk increases in clinical settings, with anemia affecting 40% of hospitalized older adults and 47% of nursing home residents. As anemia, chronic kidney disease, inflammation, and nutritional deficiencies increase with age, regular monitoring of hemoglobin and hematocrit becomes critical for diagnosis, treatment optimization, and disease management. This growing clinical need is driving steady growth in the market, as healthcare systems increasingly use point-of-care devices, automated analyzers, and routine screening protocols designed for aging populations.
Moreover, the rising global demand for surgical procedures, particularly in cardiac, orthopedic, and cancer surgeries, is driving the need for precise perioperative hematocrit monitoring as part of modern Patient Blood Management strategies. In 2024, a study published in Cardiology and Therapy reported that implementing PBM protocols in cardiovascular surgery reduced red-blood-cell transfusions by 21%, demonstrating the clinical and economic value of structured blood-management programs. In 2025, a PubMed-indexed surgical review identified key advances, including intraoperative cell salvage, low-volume autotransfusion systems, and retrograde autologous priming, all of which reduce dependence on donor blood and require continuous hematocrit assessment for safe implementation. In addition, in 2024, ERAS Cardiac guidelines further emphasized preoperative anemia optimization, restrictive transfusion thresholds, and real-time intraoperative hematocrit monitoring to improve outcomes in high-risk surgeries. The global demand for hematocrit testing is increasing as hospitals accelerate the deployment of PBM and integrate new surgical blood-conservation technologies.
This product will be delivered within 1-3 business days.
It has also been estimated that as CKD progresses, anemia rates can go up to 80% in late-stage disease. In the same year, a systematic review reported that the prevalence is up to 65% of cancer patients globally, spanning multiple tumor types. Given these disease patterns, demand for hematocrit testing continues to rise. Because hematocrit is a core component of the CBC panel used to screen and monitor these conditions, the growing disease burden is increasing demand for hematocrit testing, thereby driving the rapid growth of the global hematocrit testing market.
The growing use of automated and digital hematology analyzers is propelling market growth as healthcare systems transition to high-throughput, precision-driven diagnostic platforms. In August 2024, Abbott received FDA clearance for its Alinity h-series hematology instruments, enabling advanced, fully automated CBC and hematocrit testing with faster turnaround times and enhanced workflow efficiency. The platform combines smart sample management, digital reporting, and high analytical sensitivity to reduce manual intervention while improving laboratory performance. This trend is consistent with the broader global shift toward digitized hematology, in which AI-assisted interpretation, automated quality control, and remote connectivity are becoming standard features in modern laboratories. These innovations significantly improve testing capacity, accuracy, and clinical reliability. Therefore, the market is constantly expanding due to the increased adoption of automated analyzers, the modernization of diagnostic laboratories, and the rising need for efficient, high-volume hematological testing.
The market is experiencing strong growth opportunities as it transitions to point-of-care (POC) hematocrit testing. Rapid, near-patient diagnostics are becoming increasingly important in emergency departments, ambulances, intensive care units, and rural clinics, where immediate hematocrit assessment facilitates faster decision-making for trauma care, anemia detection, dehydration assessment, and surgical blood-loss monitoring. Rising demand for faster turnaround times is driving the adoption of portable, user-friendly hematology analyzers. For instance, in August 2023, the FDA approved PixCell Medical's HemoScreen, a point-of-care CBC device that enables direct capillary sampling and provides rapid hematocrit results, significantly improving ease of use and testing throughput. These advancements reduce manual steps, shorten wait times, and increase access to diagnostic testing in decentralized settings. As healthcare systems prioritize faster triage, decentralized workflows, and operational efficiency, the use of point-of-care hematocrit testing increases. This ongoing shift is driving overall market growth by enhancing patient outcomes and enabling real-time clinical decision support.
According to a 2024 BMC Central study, the overall prevalence of anemia among elderly people ranges between 10% and 24%, indicating a significant baseline burden. The risk increases in clinical settings, with anemia affecting 40% of hospitalized older adults and 47% of nursing home residents. As anemia, chronic kidney disease, inflammation, and nutritional deficiencies increase with age, regular monitoring of hemoglobin and hematocrit becomes critical for diagnosis, treatment optimization, and disease management. This growing clinical need is driving steady growth in the market, as healthcare systems increasingly use point-of-care devices, automated analyzers, and routine screening protocols designed for aging populations.
Moreover, the rising global demand for surgical procedures, particularly in cardiac, orthopedic, and cancer surgeries, is driving the need for precise perioperative hematocrit monitoring as part of modern Patient Blood Management strategies. In 2024, a study published in Cardiology and Therapy reported that implementing PBM protocols in cardiovascular surgery reduced red-blood-cell transfusions by 21%, demonstrating the clinical and economic value of structured blood-management programs. In 2025, a PubMed-indexed surgical review identified key advances, including intraoperative cell salvage, low-volume autotransfusion systems, and retrograde autologous priming, all of which reduce dependence on donor blood and require continuous hematocrit assessment for safe implementation. In addition, in 2024, ERAS Cardiac guidelines further emphasized preoperative anemia optimization, restrictive transfusion thresholds, and real-time intraoperative hematocrit monitoring to improve outcomes in high-risk surgeries. The global demand for hematocrit testing is increasing as hospitals accelerate the deployment of PBM and integrate new surgical blood-conservation technologies.
Global Hematocrit Testing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global hematocrit testing market report based on product, technology, sample, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables & Reagents
- Instruments
Technology Outlook (Revenue, USD Million, 2021-2033)
- Centrifugation-Based Testing
- Conductivity-Based Testing
- Optical/Photometric Methods
- Impedance-Based Methods
- Others
Sample Outlook (Revenue, USD Million, 2021-2033)
- Whole Blood
- Capillary Blood
- Venous Blood
Application Outlook (Revenue, USD Million, 2021-2033)
- Anemia Screening & Diagnosis
- Blood Loss Monitoring (Trauma, Surgery)
- Polycythemia Screening
- Chronic Disease Management (kidney disease, cancer)
- Blood Donation Centers
- Newborn & Pediatric Testing
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Diagnostic Laboratories
- Point-of-Care Settings
- Blood Banks
- Home Healthcare
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Hematocrit Testing Market: Methodology and Scope
Chapter 2. Hematocrit Testing Market: Executive Summary
Chapter 3. Hematocrit Testing Market Variables, Trends, & Scope
Chapter 4. Hematocrit Testing Market: Product Estimates & Trend Analysis
Chapter 5. Hematocrit Testing Market: Technology Estimates & Trend Analysis
Chapter 6. Hematocrit Testing Market: Sample Estimates & Trend Analysis
Chapter 7. Hematocrit Testing Market: Application Estimates & Trend Analysis
Chapter 8. Hematocrit Testing Market: End Use Estimates & Trend Analysis
Chapter 9. Hematocrit Testing Market: Regional Business Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this Hematocrit Testing market report include:- Danaher Corporation (Beckman Coulter, Inc.)
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers
- Abbott
- Medline Industries, LP
- Sysmex
- EKF Diagnostics Holdings plc.
- Boule
- Drucker Diagnostics
- HORIBA, Ltd.
- Bio-Rad Laboratories, Inc.
- Mindray
- ACON Laboratories
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.25 Billion |
| Forecasted Market Value ( USD | $ 2.01 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
